Essential Medicines for Universal Health Coverage

Medicines for Europe’s Contribution to WHO’s Biological Qualifier (BQ) Developments (PRESENTATION and SPEECH)

picto-presentationpicto-speech

 

 

 

18 October 2016
Suzette Kox
Senior Director International
Biosimilar Medicines Group

Simon-Kucher. Policy Requirements for a Sustainable Biosimilar Market (September 2016)

skp-cover

picto-reportpicto-videopicto-pr

Rebranding Medicines for Europe

Understanding the Science of Extrapolation and Defining Interchangeability – Dr. Elena Wolff-Holz, EULAR Symposium London

IMS – The Impact of Biosimilar Competition (2016)

Value Added Medicines: Rethink, Reinvent & Optimize Medicines, Improving Patient Health & Access

Factsheet: About The Value Added Medicines Group

Factsheet: What is a Value Added Medicine

Infographic: Rethink, Reinvent & Optimise Medicines, Improving Patient Health & Access